Assessment of bone profile and Liver Enzymes among molecular subtypes breast cancer patients
Keywords:
bone profile, Liver Enzymes, molecular, subtypes breast cancer
Abstract
Background: Some serum biochemical parameters may be used as prognostic markers of breast cancer; these are studied broadly, but not studied yet in Sudan.
Objective: in this study, we aimed to assess calcium, phosphate, Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), and Lactate dehydrogenase (LDH) among hormone breast cancer subtypes.
Methods: In a comparative cross‑sectional 178 BC patients, ages ranging from 28 to 95 were randomly selected. Bone minerals and liver enzymes were measured using Mindray-BS-480 Clinical Chemistry Analyzer.
Results: In total, 30.3% were triple negative, were 69.7 % hormone receptor-positive, and 52.8% out of total was in the late stage. T. test analyses show a significant difference in GGT between triple-negative and hormone receptor-positive and also between late stage and early stage (P = 0.017 and 0.016, and 0.018), respectively.
Conclusion: Hormone receptor-positive and late-stage BC patients have increased GGT activity.
References
1. Yang H, Wang R, Zeng F, Zhao J, Peng S, Ma Y, et al. Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database. Oncol Lett. 2020;20(4):87-.
2. Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone Metastasis Prognostic Factors in Breast Cancer. Breast Cancer: Basic and Clinical Research.2019;13: 1178223419830978.
3. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: a cancer journal for clinicians. 2017;67(2):93-9.
4. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology. 2010;28(20):3271-7.
5. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106.
6. Guise TA. Breast cancer bone metastases: it’s all about the neighborhood. Cell. 2013;154(5):957-9.
7. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019;144(8):1941-53.
8. Steinman RA, Brufsky AM, Oesterreich S. Zoledronic acid effectiveness against breast cancer metastases-a role for estrogen in the microenvironment? Breast Cancer Research. 2012;14(5):1-9.
9. Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. The Lancet. 2015;386(10001):1319-20.
10. Cao R, Wang L-P. Serological diagnosis of liver metastasis in patients with breast cancer. Cancer Biol Med. 2012;9(1):57-62.
11. Pusceddu S, Milione M, Procopio G. Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. Oncol Res 2011; 19: 403–6.
12. Niemela O, Alatalo P. Biomarkers of alcohol consumption and related liver disease. Scand J Clin Lab Invest 2010; 70: 305–12.
13. Corti A, Franzini M, Paolicchi A, Pompella A. Gammaglutamyl transferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 2010; 30: 1169–81.
14. Taroeno-Hariadi, K. W., Putra, Y. R., Choridah, L., Widodo, I., Hardianti, M. S., & Aryandono, T. (2021). Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival. Journal of Breast Cancer, 24(5), 417.
15. Franzini, M., Fornaciari, I., Fierabracci, V., Elawadi, H. A., Bolognesi, V., Maltinti, S., ... & Paolicchi, A. (2012). Accuracy of b‐GGT fraction for the diagnosis of non‐alcoholic fatty liver disease. Liver international, 32(4), 629-634.
16. He, W. Z., Guo, G. F., Yin, C. X., Jiang, C., Wang, F., Qiu, H. J., ... & Xia, L. P. (2013). Gamma‐glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Disease, 15(8), e443-e452.
17. Strasak AM, Goebel G, Concin H et al. Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancer. Cancer Res 2010; 70: 3586–93.
18. Forkasiewicz, A., Dorociak, M., Stach, K., Szelachowski, P., Tabola, R., & Augoff, K. (2020). The usefulness of lactate dehydrogenase measurements in current oncological practice. Cellular & Molecular Biology Letters, 25(1), 1-14.
19. Forkasiewicz, A., Dorociak, M., Stach, K., Szelachowski, P., Tabola, R., & Augoff, K. (2020). The usefulness of lactate dehydrogenase measurements in current oncological practice. Cellular & Molecular Biology Letters, 25(1), 1-14.
2. Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone Metastasis Prognostic Factors in Breast Cancer. Breast Cancer: Basic and Clinical Research.2019;13: 1178223419830978.
3. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: a cancer journal for clinicians. 2017;67(2):93-9.
4. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology. 2010;28(20):3271-7.
5. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106.
6. Guise TA. Breast cancer bone metastases: it’s all about the neighborhood. Cell. 2013;154(5):957-9.
7. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019;144(8):1941-53.
8. Steinman RA, Brufsky AM, Oesterreich S. Zoledronic acid effectiveness against breast cancer metastases-a role for estrogen in the microenvironment? Breast Cancer Research. 2012;14(5):1-9.
9. Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. The Lancet. 2015;386(10001):1319-20.
10. Cao R, Wang L-P. Serological diagnosis of liver metastasis in patients with breast cancer. Cancer Biol Med. 2012;9(1):57-62.
11. Pusceddu S, Milione M, Procopio G. Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. Oncol Res 2011; 19: 403–6.
12. Niemela O, Alatalo P. Biomarkers of alcohol consumption and related liver disease. Scand J Clin Lab Invest 2010; 70: 305–12.
13. Corti A, Franzini M, Paolicchi A, Pompella A. Gammaglutamyl transferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 2010; 30: 1169–81.
14. Taroeno-Hariadi, K. W., Putra, Y. R., Choridah, L., Widodo, I., Hardianti, M. S., & Aryandono, T. (2021). Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival. Journal of Breast Cancer, 24(5), 417.
15. Franzini, M., Fornaciari, I., Fierabracci, V., Elawadi, H. A., Bolognesi, V., Maltinti, S., ... & Paolicchi, A. (2012). Accuracy of b‐GGT fraction for the diagnosis of non‐alcoholic fatty liver disease. Liver international, 32(4), 629-634.
16. He, W. Z., Guo, G. F., Yin, C. X., Jiang, C., Wang, F., Qiu, H. J., ... & Xia, L. P. (2013). Gamma‐glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Disease, 15(8), e443-e452.
17. Strasak AM, Goebel G, Concin H et al. Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancer. Cancer Res 2010; 70: 3586–93.
18. Forkasiewicz, A., Dorociak, M., Stach, K., Szelachowski, P., Tabola, R., & Augoff, K. (2020). The usefulness of lactate dehydrogenase measurements in current oncological practice. Cellular & Molecular Biology Letters, 25(1), 1-14.
19. Forkasiewicz, A., Dorociak, M., Stach, K., Szelachowski, P., Tabola, R., & Augoff, K. (2020). The usefulness of lactate dehydrogenase measurements in current oncological practice. Cellular & Molecular Biology Letters, 25(1), 1-14.
Published
2022-12-23
Section
Articles
